<html>
<head>
<title>Clinical Evidence</title>
<meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
</head>

<body bgcolor="#999999">
<table width="777" border="0" cellpadding="0" cellspacing="0" bgcolor="000868" align="center">
  <tr> 
    <td height="64" valign="top" colspan="2"> 
      <table width="100%" border="0" cellpadding="0" cellspacing="0" bgcolor="000000" align="center">
        <tr> 
          <td width="750" height="50" valign="middle"> 
            <div align="center"> 
              <p><font color="#FFFFFF"><a name="Top"></a><img src="../Assets/MIMetoprololtitle.gif" width="500" height="50"></font></p>
            </div>
          </td>
        </tr>
      </table>
    </td>
  </tr>
  <tr> 
    <td height="26" width="54"></td>
    <td valign="top" width="723" height="26"> 
      <table width="100%" border="0" cellpadding="0" cellspacing="0">
        <tr> 
          <td width="723" height="37"><a href="SS_MIandMetoprolol.html"><img src="../Assets/CE1.gif" width="165" height="37" align="baseline" name="Short_Summary" border="0"></a><a href="ACP_MIandMetoprolol.html"><img src="../Assets/CE2.gif" width="142" height="37" name="ACP" border="0"></a><a href="CE_MIandMetoprolol.html"><img src="../Assets/CE3.gif" width="140" height="37" name="Clinical_Evidence" border="0"></a><a href="JNC6_MIandMetoprolol.html"><img src="../Assets/CE4.gif" width="77" height="37" name="JNC_VI" border="0"></a><a href="PM_MIandMetoprolol.html"><img src="../Assets/CE5.gif" width="78" height="37" name="PubMed" border="0"></a><a href="VA_MIandMetoprolol.html"><img src="../Assets/CE6.gif" width="121" height="37" border="0"></a></td>
        </tr>
      </table>
    </td>
  </tr>
  <tr> 
    <td height="44" width="54"></td>
    <td valign="top" height="44"> 
      <table width="100%" border="0" cellpadding="0" cellspacing="0">
        <tr> 
          <td width="723" height="38"><img src="../Assets/CEheader.gif" width="330" height="50" align="baseline"><img src="../Assets/CEheader2.gif" width="393" height="50" align="baseline"></td>
        </tr>
      </table>
    </td>
  </tr>
  <tr> 
    <td height="469" width="54"></td>
    <td valign="top"> 
      <table width="100%" border="0" cellpadding="0" cellspacing="0">
        <tr> 
          <td width="746" height="469" bgcolor="ffffff"> 
            <div align="center"><br>
              <table width="88%" border="1" bordercolor="#000066">
                <tr> 
                  <td colspan="2"> 
                    <div align="center"><font size="+1" color="#000000"><font face="Geneva, Arial, Helvetica, san-serif" size="3"><b>Select 
                      a condition below to view abstract</b></font></font></div>
                  </td>
                </tr>
                <tr> 
                  <td> 
                    <div align="center"> <font size="+1"><font size="3"><span class=localhead id=localhead><a href="#Acute">Acute 
                      myocardial infarction</a></span></font></font></div>
                  </td>
                  <td>
                    <div align="center"><span class=localhead id=localhead><a href="#Second">Secondary 
                      prevention of ischaemic cardiac events</a></span></div>
                  </td>
                </tr>
              </table>
              <a name="Second"><br>
              </a><br>
              <table width="93%" border="0">
<tr bordercolordark="#ffffff" bordercolorlight="#c2c2c2"> 
                  <td class=heading id=heading><TABLE cellSpacing=0 borderColorDark=#ffffff cellPadding=0 width="100%" 
borderColorLight=#c2c2c2 border=1>
                      <TBODY>
                        <TR> 
                          <TD class=heading id=heading> <div align="center">
                              <SCRIPT src="MI%20and%20betablocker011402_files/0206_i3_files/0206_i3.0"></SCRIPT>
                              <SCRIPT language=JavaScript> function showWindow(targeturl) { window.open(targeturl, ""); } </SCRIPT>
                              <font color="#B70000"><a name="2"></a> Last Updated: 
                              Janurary, 2002</font> </div>
<TABLE width="100%" border=0>
                              <TBODY>
                                <TR> 
                                  <TD align=right><SPAN class=localheadtopic 
            id=localheadtopic><SECTION>Cardiovascular disorders</SECTION></SPAN><IMG height=10 
            src="MI%20and%20betablocker011402_files/0206_i3_files/spacer.gif" width=10 align=absMiddle 
            border=0><BR>
                                    <SPAN class=localhead id=localhead><TOPIC>Secondary 
                                    prevention of ischaemic cardiac events</TOPIC><IMG height=10 
            src="MI%20and%20betablocker011402_files/0206_i3_files/spacer.gif" width=10 align=absMiddle 
            border=0></SPAN></TD>
                                </TR>
                                <TR> 
                                  <TD class=title-author id=title-author vAlign=top noWrap align=right 
          bgColor=#ffffff height=30><A 
            href="http://www.evidence.org/lpBinCE/lpext.dll?f=id&amp;id=0206_CONTRIB&amp;t=document-frame.htm&amp;2.0&amp;p="><EM>Clinical 
                                    Evidence</EM> writers on secondary prevention 
                                    of ischaemic cardiac events</A><IMG height=10 src="MI%20and%20betablocker011402_files/0206_i3_files/spacer.gif" width=10 
            align=absMiddle border=0></TD>
                                </TR>
                              </TBODY>
                            </TABLE>
                            <BR> <H1 style="DISPLAY: none; FONT-SIZE: 0pt; VISIBILITY: hidden">Other 
                              drugs</H1>
                            <TABLE cellSpacing=0 cellPadding=3 width="100%" border=0>
                              <TBODY>
                                <TR> 
                                  <TD width="10%" vAlign=top bgcolor="333333" class=question id=question><B><SPAN 
            class=question-title id=question-title><font color="ffffff">QUESTION</font></SPAN></B></TD>
                                  <TD bgcolor="cccccc" class=question id=question>&nbsp;<B>What 
                                    are the effects of other drug treatments?</B></TD>
                                </TR>
                              </TBODY>
                            </TABLE>
                            <BR>
                            <A name=I3> 
                            <H2 style="DISPLAY: none; FONT-SIZE: 0pt; VISIBILITY: hidden">ß 
                              Blockers</H2>
                            <TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>
                              <TBODY>
                                <TR class=option id=option> 
                                  <TD 
          width="10%" vAlign=top bgcolor="000099" class=option id=option style="PADDING-LEFT: 2px"><SPAN class=option-title 
            id=option-title><font color="ffffff">OPTION</font>&nbsp;&nbsp;&nbsp;</SPAN></TD>
                                  <TD 
            width="100%" bgcolor="ccccff" class=option id=option style="PADDING-LEFT: 2px"><B>ß Blockers</B></TD>
                                </TR>
                              </TBODY>
                            </TABLE>
                            </A> <TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>
                              <TBODY>
                                <TR> 
                                  <TD><A name=I3-SUMSTATEMENT><B> 
                                    <P style="MARGIN-LEFT: 3px" align=justify>We 
                                      found strong evidence from systematic reviews 
                                      of RCTs that ß blockers reduce the risk 
                                      of all cause mortality, coronary mortality, 
                                      recurrent non-fatal MI, and sudden death 
                                      in people after MI. Most benefit was seen 
                                      in those at highest risk of death after 
                                      an MI (&gt;&nbsp;50 years old; previous 
                                      MI, angina pectoris, hypertension, or treatment 
                                      with digitalis; transient mechanical or 
                                      electrical failure; higher heart rate at 
                                      study entry). About a quarter of people 
                                      suffered adverse effects.</P>
                                    </B></A></TD>
                                </TR>
                              </TBODY>
                            </TABLE>
                            <BR> <TABLE cellSpacing=0 cellPadding=3 width="100%" border=0>
                              <TBODY>
                                <TR> 
                                  <TD> <P align=justify><FONT color=#0033cc><A 
            name=I3-BENEFITS><B>Benefits: </B></A></FONT><B>Survival and reinfarction:</B> 
                                      One systematic review (search date 1993, 
                                      26 RCTs, over 24&nbsp;000 people) compared 
                                      oral ß blockers versus placebo within days 
                                      or weeks of an acute MI (late intervention 
                                      trials) and continued for between 6 weeks 
                                      to 3 years. Most RCTs followed participants 
                                      for 1 year. The review found improved survival 
                                      in people given ß blockers (RRR 23%, 95% 
                                      CI 14% to 30%). <A 
            href="http://www.evidence.org/lpBinCE/lpext.dll/BMJSPLITCE/cvd.html/0206/0206_q2/0206_i3?f=templates&amp;fn=document-frame.htm&amp;2.0#REF23">[23]</A> 
                                      One prior systematic review (search date 
                                      not stated, 24 RCTs) found that long term 
                                      use of ß blockers versus placebo after MI 
                                      reduced total mortality (RRR about 20%; 
                                      NNT 48), sudden death (RRR about 30%; NNT 
                                      63), and non-fatal reinfarction (RRR about 
                                      25%; NNT 56). <A 
            href="http://www.evidence.org/lpBinCE/lpext.dll/BMJSPLITCE/cvd.html/0206/0206_q2/0206_i3?f=templates&amp;fn=document-frame.htm&amp;2.0#REF24">[24]</A> 
                                      <B>Anginal symptoms:</B> We found no good 
                                      RCTs evaluating the antianginal effects 
                                      of ß blockers in people after MI. One trial 
                                      found atenolol more effective than placebo 
                                      in people with chronic stable effort angina 
                                      or silent ischaemia. <A 
            href="http://www.evidence.org/lpBinCE/lpext.dll/BMJSPLITCE/cvd.html/0206/0206_q2/0206_i3?f=templates&amp;fn=document-frame.htm&amp;2.0#REF25">[25]</A> 
                                      <B>Different types of ß blockers:</B> The 
                                      earlier review found no differences between 
                                      ß blockers with and without cardioselectivity 
                                      or membrane stabilising properties, but 
                                      it raised concerns about the lack of efficacy 
                                      of ß blockers with intrinsic sympathomimetic 
                                      activity in long term management after MI. 
                                      <A 
            href="http://www.evidence.org/lpBinCE/lpext.dll/BMJSPLITCE/cvd.html/0206/0206_q2/0206_i3?f=templates&amp;fn=document-frame.htm&amp;2.0#REF24">[24]</A> 
                                      One RCT (607 people after MI) found that 
                                      acebutolol, a ß blocker with moderate partial 
                                      agonist activity, decreased 1 year mortality 
                                      compared with placebo (AR of death: 11% 
                                      with placebo, 6% with acebutolol; RRR 48%, 
                                      95% CI 9% to 71%). <A 
            href="http://www.evidence.org/lpBinCE/lpext.dll/BMJSPLITCE/cvd.html/0206/0206_q2/0206_i3?f=templates&amp;fn=document-frame.htm&amp;2.0#REF26">[26]</A> 
                                      <B>Effects in different subgroups:</B> One 
                                      systematic review (search date 1983, 9 RCTs) 
                                      compared ß blockers versus placebo started 
                                      more than 24 hours after onset of symptoms 
                                      of acute MI and continued for 924 months. 
                                      <A 
            href="http://www.evidence.org/lpBinCE/lpext.dll/BMJSPLITCE/cvd.html/0206/0206_q2/0206_i3?f=templates&amp;fn=document-frame.htm&amp;2.0#REF27">[27]</A> 
                                      Pooled analysis of individual data (13&nbsp;679 
                                      people) found that the benefits of ß blockers 
                                      versus placebo on mortality seemed comparable 
                                      in men and women. The highest absolute benefit 
                                      from ß blockers was found in subgroups with 
                                      the highest baseline risks (that is, those 
                                      with the highest mortality on placebo): 
                                      those over 50 years of age; those with a 
                                      history of previous MI, angina pectoris, 
                                      hypertension, or treatment with digitalis; 
                                      those with transient signs or symptoms of 
                                      mechanical or electrical failure in the 
                                      early phases of MI; and those with a higher 
                                      heart rate at study entry. Low risk subgroups 
                                      had smaller mean absolute benefit.</P></TD>
                                </TR>
                              </TBODY>
                            </TABLE>
                            <TABLE cellSpacing=0 cellPadding=3 width="100%" border=0>
                              <TBODY>
                                <TR> 
                                  <TD> <P align=justify><FONT color=#0033cc><A name=I3-HARMS><B>Harms: 
                                      </B></A></FONT>Adverse effects include shortness 
                                      of breath, bronchospasm, bradycardia, hypotension, 
                                      heart block, cold hands and feet, diarrhoea, 
                                      fatigue, reduced sexual activity, depression, 
                                      nightmares, faintness, insomnia, blacking 
                                      out, and hallucinations. Rates vary in different 
                                      studies. One RCT reported an absolute risk 
                                      increase for any adverse effect on propranolol 
                                      compared with placebo of 24% (95% CI not 
                                      available). Serious adverse effects were 
                                      uncommon and only a small proportion of 
                                      people withdrew as a result. <A 
            href="http://www.evidence.org/lpBinCE/lpext.dll/BMJSPLITCE/cvd.html/0206/0206_q2/0206_i3?f=templates&amp;fn=document-frame.htm&amp;2.0#REF28">[28]</A> 
                                    </P></TD>
                                </TR>
                              </TBODY>
                            </TABLE>
                            <TABLE cellSpacing=0 cellPadding=3 width="100%" border=0>
                              <TBODY>
                                <TR> 
                                  <TD> <P align=justify><FONT color=#0033cc><A name=I3-COMMENT><B>Comment: 
                                      </B></A></FONT>Continued benefit has been 
                                      reported from the use of ß blockers up to 
                                      6 years after MI (ARR for mortality 5.9%, 
                                      95% CI not available; P&nbsp;=&nbsp;0.003; 
                                      RRR 18%). However, the study was not blinded 
                                      after 33 months.</P></TD>
                                </TR>
                              </TBODY>
                            </TABLE>
                            <BR>
                            <A 
      name=references></A> <TABLE cellSpacing=0 cellPadding=0 border=0>
                              <TBODY>
                                <TR> 
                                  <TD width=90 bgColor=#404040><IMG height=2 src="" width=1 
            align=absMiddle border=0></TD>
                                  <TD vAlign=bottom width="100%" bgColor=#404040><IMG height=2 src="" 
            width=1 align=absMiddle border=0></TD>
                                </TR>
                                <TR> 
                                  <TD class=key-message id=key-message width=90 
            bgColor=cccccc><B>References</B></TD>
                                  <TD width="100%">&nbsp;</TD>
                                </TR>
                              </TBODY>
                            </TABLE>
                            <BR> <TABLE cellPadding=2 width="100%" align=center>
                              <TBODY>
                                <TR><A class=reference id=reference name=REF23></a> 
                                  <TD class=reference id=reference vAlign=top width=15>23. 
                                  </TD>
                                  <TD class=reference id=reference vAlign=top width="100%">Teo 
                                    KK, Yusuf S, Furberg CD. Effects of prophylactic 
                                    antiarrhythmic drug therapy in acute myocardial 
                                    infarction. <EM>JAMA</EM> 1993;270:15891595. 
                                    Search date 1993; primary sources Medline; 
                                    hand search of reference lists; details of 
                                    unpublished trials sought from pharmaceutical 
                                    industry/other investigators. <A 
            href='javascript:showWindow("http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=93381966");' 
            style="FONT-SIZE: 8pt">[PubMed]</A></TD>
                                </TR>
                                <TR><A class=reference id=reference name=REF24></a> 
                                  <TD class=reference id=reference vAlign=top width=15>24. 
                                  </TD>
                                  <TD class=reference id=reference vAlign=top width="100%">Yusuf 
                                    S, Peto R, Lewis J, Collins R, Sleight P. 
                                    Beta blockade during and after myocardial 
                                    infarction: An overview of the randomized 
                                    trials. <EM>Prog Cardiovasc Dis</EM> 1985;27:335371. 
                                    No details of search date or primary sources 
                                    given.</TD>
                                </TR>
                                <TR><A class=reference id=reference name=REF25></a> 
                                  <TD class=reference id=reference vAlign=top width=15>25. 
                                  </TD>
                                  <TD class=reference id=reference vAlign=top width="100%">Pepine 
                                    CJ, Cohn PF, Deedwania PC, et al for the ASIST 
                                    Study Group. Effects of treatment on outcome 
                                    in mildly symptomatic patients with ischemia 
                                    during daily life: the atenolol silent ischemia 
                                    study (ASIST). <EM>Circulation</EM> 1994;90:762768. 
                                    <A 
            href='javascript:showWindow("http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=94320250");' style="FONT-SIZE: 8pt">[PubMed]</A></TD>
                                </TR>
                                <TR><A class=reference id=reference name=REF26></a> 
                                  <TD class=reference id=reference vAlign=top width=15>26. 
                                  </TD>
                                  <TD class=reference id=reference vAlign=top width="100%">Boissel 
                                    J-P, Leizerovicz A, Picolet H, et al, for 
                                    the APSI Investigators. Secondary prevention 
                                    after high-risk acute myocardial infarction 
                                    with low-dose acebutolol. <EM>Am J Cardiol</EM> 
                                    1990;66:251260. <A 
            href='javascript:showWindow("http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=90313637");' 
            style="FONT-SIZE: 8pt">[PubMed]</A></TD>
                                </TR>
                                <TR><A class=reference id=reference name=REF27></a> 
                                  <TD class=reference id=reference vAlign=top width=15>27. 
                                  </TD>
                                  <TD class=reference id=reference vAlign=top width="100%">The 
                                    Beta-Blocker Pooling Project Research Group. 
                                    The beta-blocker pooling project (BBPP): subgroup 
                                    findings from randomized trials in post infarction 
                                    patients. <EM>Eur Heart J</EM> 1988;9:816. 
                                    Search date placebo controlled trials published 
                                    by December 1983; details of primary sources 
                                    not given. <A 
            href='javascript:showWindow("http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=AMBIGUOUS 89210943, 88152021");' style="FONT-SIZE: 8pt">[PubMed]</A></TD>
                                </TR>
                                <TR><A class=reference id=reference name=REF28></a> 
                                  <TD class=reference id=reference vAlign=top width=15>28. 
                                  </TD>
                                  <TD class=reference id=reference vAlign=top 
            width="100%">Beta-blocker Heart Attack Trial Research Group. A randomized 
                                    trial of propranolol in patients with acute 
                                    myocardial infarction: I. Mortality results. 
                                    <EM>JAMA</EM> 1982;247:17071714. <A 
            href='javascript:showWindow("http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=82145830");' style="FONT-SIZE: 8pt">[PubMed]</A></TD>
                                </TR>
                              </TBODY>
                            </TABLE>
                            <TABLE width="100%" border=0>
                              <TBODY>
                                <TR> 
                                  <TD vAlign=bottom width="50%"> 
                                  
                              <TD align=right width="50%"><IMG 
            alt="BMJ - Clinical Evidence" src="../Assets/ce-pagebrand.jpg" 
            border=0 width="89" height="44"></TD>
                                </TR>
                                <TR> 
                                  <TD align=left width="50%"> 
                                  <TD align=right width="50%"><A 
            href="http://www.evidence.org/lpBinCE/lpext.dll?f=id&amp;id=201106&amp;t=document-frame.htm&amp;p=copyright.html&amp;2.0"><SPAN 
            style="FONT-SIZE: 8pt; font-face: arial">© 2001 BMJ Publishing Group</SPAN></A></TD>
                                </TR>
                              </TBODY>
                            </TABLE>
                            <SCRIPT language=JavaScript>
			var purl = "0206.PDF"; 
</SCRIPT> 
                            <SCRIPT language=JavaScript src="MI%20and%20betablocker011402_files/0206_i3_files/stats.js" 
      type=text/javascript></SCRIPT> <SCRIPT language=JavaScript type=text/javascript><!--
  stats("MC-MTg0OQ==-45MT-Y2Nz","","","");
//--></SCRIPT> <NOSCRIPT>
                            <IMG height=1 src="" width=1 
  border=0></NOSCRIPT></TD>
                        </TR>
                      </TBODY>
                    </TABLE> </td>
                </tr>
                <tr> 
                  <td>
                    <div align="right"><a href="#Top"><img src="../Assets/Top.gif" width="76" height="37" border="0"></a></div>
                  </td>
                </tr>
              </table>
              <a name="Acute"></a><br>
              <table width="93%" border="0">
                <tr bordercolordark="#ffffff" bordercolorlight="#c2c2c2"> 
                  <td class=heading id=heading><TABLE border=1 borderColorDark=#ffffff borderColorLight=#c2c2c2 cellPadding=0 
cellSpacing=0 width="100%" align="center">
                      <TBODY>
                        <TR> 
                          <TD class=heading id=heading><TABLE cellSpacing=0 borderColorDark=#ffffff cellPadding=0 width="100%" 
borderColorLight=#c2c2c2 border=1>
                              <TBODY>
                                <TR> 
                                  <TD class=heading id=heading> <div align="center">
                                      <SCRIPT src="MI_and_metoprolol%20092101/0202_i3_files/0202_i3.0"></SCRIPT>
                                      <SCRIPT language=JavaScript> function showWindow(targeturl) { window.open(targeturl, ""); } </SCRIPT>
                                      <font color="#B70000">Last Updated: September, 
                                      2001</font> </div>
<TABLE width="100%" border=0>
                                      <TBODY>
                                        <TR> 
                                          <TD align=right><SPAN class=localheadtopic 
            id=localheadtopic><SECTION>Cardiovascular disorders</SECTION></SPAN><IMG height=10 
            src="MI_and_metoprolol%20092101/0202_i3_files/spacer.gif" width=10 align=absMiddle 
            border=0><BR>
                                            <SPAN class=localhead id=localhead><TOPIC>Acute 
                                            myocardial infarction</TOPIC><IMG height=10 
            src="MI_and_metoprolol%20092101/0202_i3_files/spacer.gif" width=10 align=absMiddle 
            border=0></SPAN></TD>
                                        </TR>
                                        <TR> 
                                          <TD class=title-author id=title-author vAlign=top noWrap align=right 
          bgColor=#ffffff height=30>Shamir Mehta<IMG height=10 src="MI_and_metoprolol%20092101/0202_i3_files/spacer.gif" width=10 
            align=absMiddle border=0></TD>
                                        </TR>
                                      </TBODY>
                                    </TABLE>
                                    <BR> <H1 
      style="DISPLAY: none; FONT-SIZE: 0pt; VISIBILITY: hidden">Treatments</H1>
                                    <TABLE cellSpacing=0 cellPadding=3 width="100%" border=0>
                                      <TBODY>
                                        <TR> 
                                          <TD width="10%" vAlign=top bgcolor="333333" class=question id=question><B><SPAN 
            class=question-title id=question-title><font color="ffffff">QUESTION</font></SPAN></B></TD>
                                          <TD bgcolor="cccccc" class=question id=question>&nbsp;<B>Which 
                                            treatments improve outcomes in acute 
                                            myocardial infarction?</B></TD>
                                        </TR>
                                      </TBODY>
                                    </TABLE>
                                    <BR>
                                    <A name=I3> 
                                    <H2 style="DISPLAY: none; FONT-SIZE: 0pt; VISIBILITY: hidden">ß 
                                      Blockers</H2>
                                    <TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>
                                      <TBODY>
                                        <TR class=option id=option> 
                                          <TD 
          width="10%" vAlign=top bgcolor="000099" class=option id=option style="PADDING-LEFT: 2px"><SPAN class=option-title 
            id=option-title><font color="ffffff">OPTION&nbsp;</font>&nbsp;&nbsp;</SPAN></TD>
                                          <TD 
            width="100%" bgcolor="ccccff" class=option id=option style="PADDING-LEFT: 2px"><B>ß Blockers</B></TD>
                                        </TR>
                                      </TBODY>
                                    </TABLE>
                                    </A> <TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>
                                      <TBODY>
                                        <TR> 
                                          <TD><A name=I3-SUMSTATEMENT><B> 
                                            <P style="MARGIN-LEFT: 3px" align=justify>Systematic 
                                              reviews of RCTs have found that 
                                              oral ß blockers given within hours 
                                              of infarction reduce both mortality 
                                              and reinfarction in people with 
                                              AMI. Adding ß blockers to thrombolytic 
                                              treatment confers additional benefit. 
                                              Most benefit is obtained from long 
                                              term use of ß blockers.</P>
                                            </B></A></TD>
                                        </TR>
                                      </TBODY>
                                    </TABLE>
                                    <BR> <TABLE cellSpacing=0 cellPadding=3 width="100%" border=0>
                                      <TBODY>
                                        <TR> 
                                          <TD> <P align=justify><FONT color=#0033cc><A 
            name=I3-BENEFITS><B>Benefits: </B></A></FONT><B>Given within hours 
                                              of infarction:</B> We found three 
                                              systematic reviews (search date 
                                              1997, <A 
            href="#references">[16]</A> search date not stated, <A 
            href="#references">[17]</A> search date 1987 <A 
            href="#references">[18]</A> ) of early use of ß blockers. The older 
                                              reviews identified 27 RCTs and found 
                                              that, within 1 week of treatment, 
                                              ß blockers significantly reduced 
                                              the risk of death and major vascular 
                                              events (RR for the combined outcome 
                                              of death, non-fatal cardiac arrest, 
                                              or non-fatal reinfarction 0.84, 
                                              1110 events <EM>v</EM> 1298 events, 
                                              95% CI not available, P&nbsp;&lt;&nbsp;0.001). 
                                              The largest of the RCTs (16&nbsp;027 
                                              people with AMI) compared intravenous 
                                              atenolol 510&nbsp;mg given immediately 
                                              followed by 100&nbsp;mg orally given 
                                              daily for 7 days versus standard 
                                              treatment (no ß blocker). <A 
            href="#references">[19]</A> After 7 days, atenolol reduced vascular 
                                              mortality compared with control 
                                              (3.9% with atenolol <EM>v</EM> 4.6% 
                                              with control; ARR 0.7%; RR 0.85, 
                                              95% CI 0.73 to 0.88; NNT 147). The 
                                              RCT found more benefit in people 
                                              with ECG evidence of AMI at entry 
                                              (in people with ECG suggesting anterior 
                                              infarction, inferior infarction, 
                                              both, or bundle branch block, AR 
                                              of death 5.33% on atenolol, 6.49% 
                                              for controls; ARR 1.16%; NNT 86, 
                                              95% CI not available). People older 
                                              than 65 years and those with large 
                                              infarcts had the most benefit. <A 
            href="#references">[19]</A> The recent systematic review (search date 
                                              1997, 82 RCTs, 54 234 people) <A 
            href="#references">[16]</A> separately analysed 51 short term RCTs 
                                              (up to 6 weeks after the onset of 
                                              pain) and 31 long term RCTs. Most 
                                              of the RCTs did not include thrombolysis. 
                                              In the short term studies seven 
                                              RCTs reported no deaths, and many 
                                              reported only a few. Meta-analysis 
                                              of the RCTs that reported at least 
                                              one death found that ß blockers 
                                              versus placebo reduced mortality, 
                                              but the reduction was not significant 
                                              in the short term (ARR 0.4%, OR 
                                              0.96, 95% CI 0.85 to 1.08).<font color="#FF0000"> 
                                              In the longer term RCTs, ß blockers 
                                              versus placebo significantly reduced 
                                              mortality over 6 months to 4 years 
                                              (OR 0.77, 95% CI 0.69 to 0.85). 
                                              About 84 people would need treatment 
                                              for 1 year to avoid one death. No 
                                              significant difference in effectiveness 
                                              was found between different types 
                                              of ß blocker (based on cardioselectivity 
                                              or intrinsic sympathomimetic activity). 
                                              Most evidence was obtained with 
                                              propranolol, timolol, and metoprolol.</font> 
                                              <B>In people receiving thrombolytic 
                                              treatment: </B>We found one RCT 
                                              (1434 people with AMI), which compared 
                                              early versus delayed metoprolol 
                                              in people who had been given thombolysis 
                                              (tPA). <A 
            href="#references">[20]</A> Early treatment began on day 1 (intravenous 
                                              then oral) and delayed treatment 
                                              on day 6 (oral). At 6 days, people 
                                              receiving early treatment had significantly 
                                              lower rates of reinfarction (AR 
                                              2.7% early<EM><EM>v</EM></EM>5.1% 
                                              delayed, 95% CI not available, P&nbsp;=&nbsp;0.02) 
                                              and recurrent chest pain (AR 18.8%<EM><EM>v</EM></EM>24.1%, 
                                              P&nbsp;&lt;&nbsp;0.02). There were 
                                              no early (6 days) or late (1 year) 
                                              differences observed in mortality 
                                              or left ventricular ejection fraction 
                                              between the two groups. <B>Long 
                                              term use:</B> <A 
            href="#2"><b><font color="#FF0000">See ß blockers under secondary 
                                              prevention of ischaemic cardiac 
                                              events</font></b></A>.</P></TD>
                                        </TR>
                                      </TBODY>
                                    </TABLE>
                                    <TABLE cellSpacing=0 cellPadding=3 width="100%" border=0>
                                      <TBODY>
                                        <TR> 
                                          <TD> <P align=justify><FONT color=#0033cc><A name=I3-HARMS><B>Harms: 
                                              </B></A></FONT>People with asthma 
                                              or severe congestive cardiac failure 
                                              were excluded from most trials. 
                                              Many of the early trials tended 
                                              to enrol people at low risk of death 
                                              soon after AMI. In people given 
                                              immediate rather than delayed ß 
                                              blockers following tPA, there was 
                                              a non-significantly increased frequency 
                                              of heart failure during the initial 
                                              admission to hospital (15.3%<EM> 
                                              v</EM> 12.2%, P&nbsp;=&nbsp;0.10). 
                                              <A 
            href="#references">[20]</A> The presence of first degree heart block 
                                              and bundle branch block was associated 
                                              with an increased frequency of adverse 
                                              events.</P></TD>
                                        </TR>
                                      </TBODY>
                                    </TABLE>
                                    <TABLE cellSpacing=0 cellPadding=3 width="100%" border=0>
                                      <TBODY>
                                        <TR> 
                                          <TD> <P align=justify><FONT color=#0033cc><A name=I3-COMMENT><B>Comment: 
                                              </B></A></FONT>ß Blockers may reduce 
                                              rates of cardiac rupture and ventricular 
                                              fibrillation. This may explain why 
                                              people older than 65 years and those 
                                              with large infarcts benefited most, 
                                              as they also have higher rates of 
                                              these complications. The trials 
                                              were mostly conducted in the prethrombolytic 
                                              era. The trial comparing early versus 
                                              delayed ß blockade following thrombolysis 
                                              was too small to rule out an effect 
                                              on mortality of ß blockers when 
                                              added to thrombolysis. <A 
            href="#references">[20]</A> </P></TD>
                                        </TR>
                                      </TBODY>
                                    </TABLE>
                                    <BR>
                                    <A name=references></A> <TABLE cellSpacing=0 cellPadding=0 border=0>
                                      <TBODY>
                                        <TR> 
                                          <TD width=90 bgColor=#404040><IMG height=2 src="" width=1 
            align=absMiddle border=0></TD>
                                          <TD vAlign=bottom width="100%" bgColor=#404040><IMG height=2 src="" 
            width=1 align=absMiddle border=0></TD>
                                        </TR>
                                        <TR> 
                                          <TD class=key-message id=key-message width=90 
            bgColor=cccccc><B>References</B></TD>
                                          <TD width="100%">&nbsp;</TD>
                                        </TR>
                                      </TBODY>
                                    </TABLE>
                                    <BR> <TABLE cellPadding=2 width="100%" align=center>
                                      <TBODY>
                                        <TR><A class=reference id=reference name=REF16></a> 
                                          <TD class=reference id=reference vAlign=top width=15 height="47">16. 
                                          </TD>
                                          <TD class=reference id=reference vAlign=top width="100%" height="47">Freemantle 
                                            N, Cleland J, Young P, Mason J, Harrison 
                                            J. Beta blockade after myocardial 
                                            infarction: systematic review and 
                                            meta regression analysis. <EM>BMJ 
                                            </EM>1999;318:17301737. Search date 
                                            1997; primary sources Medline, Embase, 
                                            Biosis, Healthstar, Sigle, IHTA, Derwent 
                                            drug file, dissertation abstracts, 
                                            Pascal, international pharmaceutical 
                                            abstracts, science citation index, 
                                            and handsearch of reference lists.</TD>
                                        </TR>
                                        <TR><A class=reference id=reference name=REF17></a> 
                                          <TD class=reference id=reference vAlign=top width=15 height="44">17. 
                                          </TD>
                                          <TD class=reference id=reference vAlign=top width="100%" height="44">Yusuf 
                                            S, Peto R, Lewis S, et al. Beta-blockade 
                                            during and after myocardial infarction: 
                                            an overview of the randomized trials. 
                                            <EM>Prog Cardiovasc Dis</EM> 1985;27:355371. 
                                            Search date not stated; primary sources 
                                            computer-aided search of the literature; 
                                            manual search of reference lists; 
                                            and enquiries to colleagues about 
                                            relevant papers.</TD>
                                        </TR>
                                        <TR><A class=reference id=reference name=REF18></a> 
                                          <TD class=reference id=reference vAlign=top width=15>18. 
                                          </TD>
                                          <TD class=reference id=reference vAlign=top width="100%">Sleight 
                                            P for the ISIS Study Group. Beta blockade 
                                            early in acute myocardial infarction. 
                                            <EM>Am J Cardiol</EM> 1987;60:6A12A.</TD>
                                        </TR>
                                        <TR><A class=reference id=reference name=REF19></a> 
                                          <TD class=reference id=reference vAlign=top width=15>19. 
                                          </TD>
                                          <TD class=reference id=reference vAlign=top width="100%">First 
                                            International Study of Infarct Survival 
                                            (ISIS-1). Randomised trial of intravenous 
                                            atenolol among 16&nbsp;027 cases of 
                                            suspected acute myocardial infarction. 
                                            <EM>Lancet</EM> 1986;ii:5766.</TD>
                                        </TR>
                                        <TR><A class=reference id=reference name=REF20></a> 
                                          <TD class=reference id=reference vAlign=top width=15>20. 
                                          </TD>
                                          <TD class=reference id=reference vAlign=top width="100%">Roberts 
                                            R, Rogers WJ, Mueller HS, et al. Immediate 
                                            versus deferred beta-blockade following 
                                            thrombolytic therapy in patients with 
                                            acute myocardial infarction: results 
                                            of the thrombolysis in myocardial 
                                            infarction (TIMI) II-B study. <EM>Circulation</EM> 
                                            1991;83:422437.</TD>
                                        </TR>
                                      </TBODY>
                                    </TABLE>
                                    <TABLE width="100%" border=0>
                                      <TBODY>
                                        <TR> 
                                          <TD vAlign=bottom width="50%"> 
                                          
                                    <TD align=right width="50%"><IMG 
            alt="BMJ - Clinical Evidence" src="../Assets/ce-pagebrand.jpg" 
            border=0 width="89" height="44"></TD>
                                        </TR>
                                        <TR> 
                                          <TD align=left width="50%"><SPAN 
            style="FONT-SIZE: 8pt; font-face: arial">Issue 5 - June 2001</SPAN></TD>
                                          <TD align=right width="50%"><SPAN 
            style="FONT-SIZE: 8pt; font-face: arial">© 2001 BMJ Publishing Group</SPAN></TD>
                                        </TR>
                                      </TBODY>
                                    </TABLE>
                                    <SCRIPT language=JavaScript>
			var purl = "0202.PDF"; 
</SCRIPT> </TD>
                                </TR>
                              </TBODY>
                            </TABLE> </TD>
                        </TR>
                      </TBODY>
                    </TABLE> </td>
                </tr>
                <tr> 
                  <td> 
                    <div align="right"><a href="#Top"><img src="../Assets/Top.gif" width="76" height="37" border="0"></a></div>
                  </td>
                </tr>
              </table>
              <p>&nbsp;</p>
            </div>
          </td>
        </tr>
      </table>
    </td>
  </tr>
  <tr> 
    <td height="28" width="54"></td>
    <td valign="top"> 
      <table width="100%" border="0" cellpadding="0" cellspacing="0" bgcolor="#55C6C6">
        <tr> 
          <td width="723" height="28" bgcolor="#3333FF"> 
            
          </td>
        </tr>
      </table>
    </td>
  </tr>
</table>
</body>
</html>
